BOBCAT Trademark
Trademark Overview
On Tuesday, October 3, 2023, a trademark application was filed for BOBCAT with the United States Patent and Trademark Office. The USPTO has given the BOBCAT trademark a serial number of 98207353. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, September 24, 2024. This trademark is owned by Elixirgen Therapeutics, Inc.. The BOBCAT trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:
Pharmaceutical preparations, namely, RNA dosage medium preparations carrying genes encoding proteins for treating or preventing genetic diseases; pharmaceutical preparations, namely, RNA dosage medium preparations carrying genes encoding proteins for treating or preventing infectious diseases; pharmaceutical preparations, namely, RNA dosage medium preparations carrying genes encoding proteins for treating or preventing cancers; pharmaceutical preparations, namely, RNA dosage medium preparations carrying genes encoding proteins for treating or preventing age-related diseases; pharmaceutical preparations, namely, RNA dosage medium preparations carrying genes encoding ribonucleoprotein constructs for gene editing being for the treatment of genetic disorders; pharmaceutical preparations, namely, RNA dosage medium preparations carrying genes encoding ribonucleoprotein constructs for treating genetic disorders in the nature of telomere shortening; pharmaceutical preparations, namely, RNA dos...
Development of pharmaceutical products for others; pharmaceutical product quality testing and evaluation for others; research and development of pharmaceutical products for others; research and development of medical products for others; research and development of pharmaceuticals for the treatment of age-related diseases and cancer; pharmaceutical products development; pharmaceutical research services; pharmaceutical research and development; research and development in the pharmaceutical and biotechnology fields; research and development in the field of medical products
General Information
| Serial Number | 98207353 |
| Word Mark | BOBCAT |
| Filing Date | Tuesday, October 3, 2023 |
| Status | 688 - NOTICE OF ALLOWANCE - ISSUED |
| Status Date | Tuesday, September 24, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, July 30, 2024 |
Trademark Statements
| Goods and Services | Pharmaceutical preparations, namely, RNA dosage medium preparations carrying genes encoding proteins for treating or preventing genetic diseases; pharmaceutical preparations, namely, RNA dosage medium preparations carrying genes encoding proteins for treating or preventing infectious diseases; pharmaceutical preparations, namely, RNA dosage medium preparations carrying genes encoding proteins for treating or preventing cancers; pharmaceutical preparations, namely, RNA dosage medium preparations carrying genes encoding proteins for treating or preventing age-related diseases; pharmaceutical preparations, namely, RNA dosage medium preparations carrying genes encoding ribonucleoprotein constructs for gene editing being for the treatment of genetic disorders; pharmaceutical preparations, namely, RNA dosage medium preparations carrying genes encoding ribonucleoprotein constructs for treating genetic disorders in the nature of telomere shortening; pharmaceutical preparations, namely, RNA dosage medium preparations carrying genes encoding proteins for regenerative medicine in the nature of cell rejuvenation |
| Goods and Services | Development of pharmaceutical products for others; pharmaceutical product quality testing and evaluation for others; research and development of pharmaceutical products for others; research and development of medical products for others; research and development of pharmaceuticals for the treatment of age-related diseases and cancer; pharmaceutical products development; pharmaceutical research services; pharmaceutical research and development; research and development in the pharmaceutical and biotechnology fields; research and development in the field of medical products |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, October 12, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, October 12, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Elixirgen Therapeutics, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Baltimore, MD 21205 |
| Party Name | Elixirgen Therapeutics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Baltimore, MD 21205 |
Trademark Events
| Event Date | Event Description |
| Friday, October 6, 2023 | NEW APPLICATION ENTERED |
| Thursday, October 12, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, May 23, 2024 | ASSIGNED TO EXAMINER |
| Wednesday, May 29, 2024 | NON-FINAL ACTION E-MAILED |
| Wednesday, May 29, 2024 | NON-FINAL ACTION WRITTEN |
| Wednesday, May 29, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, June 20, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, June 20, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, June 21, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Thursday, June 20, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, July 30, 2024 | PUBLISHED FOR OPPOSITION |
| Wednesday, July 10, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, July 30, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, September 24, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Wednesday, November 27, 2024 | TEAS STATEMENT OF USE RECEIVED |
